New article published in "Platform Life Sciences" presenting ATRIVA approach

A new article has been published in the German publication "Platform Life Sciences" written by Prof. Oliver Planz highlighting the ATRIVA approach:

Weiterlesen

Invited keynote lecture on ATRIVAs antiviral MEK inhibitor technology presented at the Annual Meeting of the German Pharmaceutical Society (DPhG)

Atriva scientists were invited to give a keynote lecture on their antiviral MEK inhibitor concept at the Annual Meeting of the German Pharmaceutical Society (DPhG).

Weiterlesen

Atriva reaches a development milestone and receives an additional tranche of running seed financing to develop its influenza therapeutic to clinical stage

The next generation of Antiviral Therapies: Co-Led by Stichting Participatie Atriva and High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received a second tranche of its running seed financing in total of € 3 Mn from Dutch, German and Canadian investors, after lead compound ATR-002 (Atriva’s antiviral MEK-Inhibitor against Influenza) has passed an important preclinical milestone paving the way to clinical development stage.

Weiterlesen

New Image Video of ATRIVA available!

A new image video of ATRIVA has been created, highlighting the imporant features of our approach against Influenza and other viral diseases.

Don't miss this opportunity to get to know ATRIVA a bit better and listen to our CSO, Prof. Oliver Planz, and our CEO, Dr. Rainer Lichtenberger, by watching the video on the newspage.

Here you can start the video by clicking on it.

 

ATRIVA scientists present MEK inhibitor technology at International Conference of Antiviral Research in Atlanta

Atriva scientists were invited to give an overview talk on their antiviral MEK inhibitor concept at the 30th International Conference of Antiviral Research (ICAR2017) that was held from May 21-25, 2017, in Atlanta/Georgia.

The annual ICAR is the most important conference series in the antiviral research field and gathers experts from academia and the industry.

Weiterlesen